AR035915A1 - Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar - Google Patents
Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y arInfo
- Publication number
- AR035915A1 AR035915A1 ARP010102374A ARP010102374A AR035915A1 AR 035915 A1 AR035915 A1 AR 035915A1 AR P010102374 A ARP010102374 A AR P010102374A AR P010102374 A ARP010102374 A AR P010102374A AR 035915 A1 AR035915 A1 AR 035915A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- phenyl
- pharmaceutically acceptable
- acceptable salts
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 230000003001 depressive effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- -1 {(2R) -2- [4- (4- {2 - [(methylsulfonyl) -amino] ethyl} phenyl) phenyl] propyl} [(methylethyl) sulfonyl] amine Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Compuesto de {(2R)-2-[4-(4-{2-[(metilsulfonil)-amino]etil}fenil)fenil]propil}[(metiletil)sulfonil]amina y sales farmacéuticamente aceptables del mismo; composiciones farmacéuticas que comprenden dicho compuesto; o dichas sales farmacéuticamente aceptables; método para potenciar la función glutamato; para tratar estados depresivos, la esquizofrenia y trastornos cognitivos de pacientes; artículos de manufactura que comprenden dicho compuesto o dichas sales farmacéuticamente aceptables y composiciones farmacéuticas que comprenden dicho compuesto. Se describe y reivindica el compuesto de sulfonamida mencionado de fórmula (1) y sales farmacéuticamente aceptables del mismo, aplicables en el tratamiento de dolencias asociadas con la hipofunción glutamato tal como trastornos psiquiátricos y neurológicos y composiciones farmacéuticas formuladas para el tratamiento de las dolencias mencionadas, que incluyen dicho compuesto como componente activo. Además se describen y reivindican los objetos restantes, detallados en el título. Composiciones farmacéuticas que comprenden el compuesto o sus sales farmacéuticamente aceptables; método para potenciar la función glutamato; para tratar estados depresivos, la esquizofrenia y trastornos cognitivos de pacientes y artículos de manufactura que comprenden dicho compuesto o dichas sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20600300P | 2000-05-19 | 2000-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035915A1 true AR035915A1 (es) | 2004-07-28 |
Family
ID=22764580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102374A AR035915A1 (es) | 2000-05-19 | 2001-05-18 | Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20030225163A1 (es) |
| EP (1) | EP1311474A1 (es) |
| JP (1) | JP2003534316A (es) |
| KR (1) | KR20030007644A (es) |
| CN (1) | CN1429205A (es) |
| AR (1) | AR035915A1 (es) |
| AU (1) | AU2001259053A1 (es) |
| BR (1) | BR0110874A (es) |
| CA (1) | CA2409830A1 (es) |
| CZ (1) | CZ20023797A3 (es) |
| DZ (1) | DZ3343A1 (es) |
| EA (1) | EA200201234A1 (es) |
| EC (1) | ECSP014078A (es) |
| HR (1) | HRP20020918A2 (es) |
| HU (1) | HUP0302255A3 (es) |
| IL (1) | IL152156A0 (es) |
| MX (1) | MXPA02010020A (es) |
| NO (1) | NO20025459D0 (es) |
| PE (1) | PE20020052A1 (es) |
| PL (1) | PL358180A1 (es) |
| SK (1) | SK16312002A3 (es) |
| SV (1) | SV2002000459A (es) |
| WO (1) | WO2001090057A1 (es) |
| ZA (1) | ZA200208749B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| US6984756B2 (en) | 2000-05-19 | 2006-01-10 | Eli Lilly And Company | Process for preparing biphenyl compounds |
| ES2225558T3 (es) | 2000-06-13 | 2005-03-16 | Eli Lilly And Company | Derivados de sulfonamida. |
| EP1438036A2 (en) * | 2001-10-12 | 2004-07-21 | Eli Lilly And Company | Use of sulfonamide derivatives as pharmaceuticals compounds |
| WO2005013961A1 (en) * | 2003-07-17 | 2005-02-17 | Eli Lilly And Company | Combination therapy for treatment of cognitive disorders or psychoses |
| EP2102153A1 (en) * | 2006-12-11 | 2009-09-23 | Eli Lilly & Company | Ampa receptor potentiators |
| BR112015031249A2 (pt) | 2013-06-13 | 2017-07-25 | Veroscience Llc | método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525099B1 (en) * | 1998-07-31 | 2003-02-25 | Eli Lilly And Company | N-substituted sulfonamide derivatives |
-
2001
- 2001-05-04 HR HR20020918A patent/HRP20020918A2/hr not_active Application Discontinuation
- 2001-05-04 MX MXPA02010020A patent/MXPA02010020A/es unknown
- 2001-05-04 PL PL01358180A patent/PL358180A1/xx not_active Application Discontinuation
- 2001-05-04 AU AU2001259053A patent/AU2001259053A1/en not_active Abandoned
- 2001-05-04 CZ CZ20023797A patent/CZ20023797A3/cs unknown
- 2001-05-04 JP JP2001586247A patent/JP2003534316A/ja not_active Withdrawn
- 2001-05-04 SK SK1631-2002A patent/SK16312002A3/sk unknown
- 2001-05-04 DZ DZ013343A patent/DZ3343A1/fr active
- 2001-05-04 HU HU0302255A patent/HUP0302255A3/hu unknown
- 2001-05-04 CA CA002409830A patent/CA2409830A1/en not_active Abandoned
- 2001-05-04 EA EA200201234A patent/EA200201234A1/ru unknown
- 2001-05-04 WO PCT/US2001/011747 patent/WO2001090057A1/en not_active Ceased
- 2001-05-04 BR BR0110874-3A patent/BR0110874A/pt not_active Application Discontinuation
- 2001-05-04 EP EP01932536A patent/EP1311474A1/en not_active Withdrawn
- 2001-05-04 CN CN01809667A patent/CN1429205A/zh active Pending
- 2001-05-04 IL IL15215601A patent/IL152156A0/xx unknown
- 2001-05-04 KR KR1020027015545A patent/KR20030007644A/ko not_active Withdrawn
- 2001-05-04 US US10/258,159 patent/US20030225163A1/en not_active Abandoned
- 2001-05-18 AR ARP010102374A patent/AR035915A1/es unknown
- 2001-05-18 SV SV2001000459A patent/SV2002000459A/es not_active Application Discontinuation
- 2001-05-18 PE PE2001000451A patent/PE20020052A1/es not_active Application Discontinuation
- 2001-05-18 EC EC2001004078A patent/ECSP014078A/es unknown
-
2002
- 2002-10-29 ZA ZA200208749A patent/ZA200208749B/en unknown
- 2002-11-14 NO NO20025459A patent/NO20025459D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2409830A1 (en) | 2001-11-29 |
| EP1311474A1 (en) | 2003-05-21 |
| HUP0302255A2 (hu) | 2003-11-28 |
| SK16312002A3 (sk) | 2003-05-02 |
| NO20025459L (no) | 2002-11-14 |
| PE20020052A1 (es) | 2002-02-02 |
| CN1429205A (zh) | 2003-07-09 |
| IL152156A0 (en) | 2003-05-29 |
| CZ20023797A3 (cs) | 2003-04-16 |
| NO20025459D0 (no) | 2002-11-14 |
| KR20030007644A (ko) | 2003-01-23 |
| ECSP014078A (es) | 2002-02-25 |
| BR0110874A (pt) | 2003-02-11 |
| JP2003534316A (ja) | 2003-11-18 |
| PL358180A1 (en) | 2004-08-09 |
| WO2001090057A1 (en) | 2001-11-29 |
| AU2001259053A1 (en) | 2001-12-03 |
| DZ3343A1 (fr) | 2001-11-29 |
| HRP20020918A2 (en) | 2004-02-29 |
| MXPA02010020A (es) | 2003-02-12 |
| ZA200208749B (en) | 2004-01-30 |
| US20030225163A1 (en) | 2003-12-04 |
| HUP0302255A3 (en) | 2005-11-28 |
| EA200201234A1 (ru) | 2003-04-24 |
| SV2002000459A (es) | 2002-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
| ES2282685T3 (es) | Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer. | |
| PA8559101A1 (es) | Inhibidores del factor xa y de las otras proteasas de serina implicadas en la cascada de la coagulacion | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR042342A1 (es) | Derivados de pirazina que presentan efecto inhibidor selectivo sobre gsk3, proceso de preparacion y formulaciones farmaceuticas que los contienen | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| ECSP088593A (es) | 5-(arilsulfonil)-pirazolopiperidinas | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| DK1776349T3 (da) | 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE) | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| UY26481A1 (es) | Inhibidores de n - (5 - ( ( (5 - alquil - 2 - oxazolil) metil) tio) - 2 - tiazolil) - carboxamida de cinasas dependientes de ciclina. | |
| DK1789398T3 (da) | 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE) | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
| AR035915A1 (es) | Compuesto de {(2r)-2-[4-(4-{2-[(-metilsulfonil) amino]-etil} fenil) fenil) propil} [(metiletil) sulfonil) amina y sales farmaceuticamente aceptables del mismo; composiciones farmaceuticas que comprenden dicho compuesto; metodo para potenciar la funcion glutamato; para tratar estados depresivos; y ar | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |